Contact Us
- 0904.634.288, 024.8888.4288
- [email protected]
- Facebook Fanpage: http://fb.com/dauthau.info
- Messenger: http://m.me/dauthau.info
Contact Us
| No | Medicine code | Active ingredient name | Technical criteria group | Concentration or content | How to use | Dosage form | Unit | Quantity | Feature |
|---|---|---|---|---|---|---|---|---|---|
1 |
1 |
Influenza vaccine (inactivated fragment vaccine containing: 4 strains) |
N1/n2/n3/n4/n5 |
Each dose of 0.5ml contains 15 mcg HA |
Intramuscularly or subcutaneous |
Injection |
Bottle/Vial/Tube/Syringe/Dose/Box |
1.000 |
|
2 |
2 |
Pure antigen inactivates influenza A H1N1 virus Pure antigen inactivates influenza A H3N2 virus Pure antigen inactivates influenza B virus |
N1/n2/n3/n4/n5 |
(15mcg type A (H1N1) + 15mcg type A (H3N2) + 15mcg type B)/0.5ml |
Inject |
Injection |
Bottle/Vial/Tube/Syringe/Dose/Box |
600 |
|
3 |
3 |
Vaccine: Rotavirus |
N1/n2/n3/n4/n5 |
Each 2ml of solution contains: Rotavirus G1 human-bovine reassortant ≥ 2.2 million IU; Rotavirus G2 human-bovinereassortant ≥ 2.8 million IU; Rotavirus G3 human-bovinereassortant ≥ 2.2 million IU; Rotavirus G4 human-bovinereassortant ≥ 2.0 million IU; Rotavirus P1A[8] human-bovinereassortant ≥ 2.3 million IU or equivalent |
Drink |
Drinking solution/oral solution |
Bottle/Vial/Tube/Syringe/Dose/Box |
200 |
|
4 |
4 |
Rabies vaccine |
N1/n2/n3/n4/n5 |
≥ 2.5 IU/0.5ml |
Inject |
East dried powder injected |
Bottle/Vial/Tube/Syringe/Dose/Box |
7.000 |
|
5 |
5 |
Japanese encephalitis vaccine (purified, inactivated Japanese encephalitis virus (SA 14-14-2 strain) |
N1/n2/n3/n4/n5 |
3mcg/0.5ml |
Intramuscularly or subcutaneous |
Injection |
Bottle/Vial/Tube/Syringe/Dose/Box |
200 |
|
6 |
6 |
Japanese encephalitis vaccine (purified, inactivated Japanese encephalitis virus (SA 14-14-2 strain) |
N1/n2/n3/n4/n5 |
6 mcg/0.5ml |
Intramuscularly or subcutaneous |
Injection |
Bottle/Vial/Tube/Syringe/Dose/Box |
200 |
|
7 |
7 |
Japanese virus nakayama structure is inactivated, pure |
N1/n2/n3/n4/n5 |
1ml/dose |
Injection or subcutaneous injection |
Injection solution |
Bottle/Vial/Tube/Syringe/Dose/Box |
200 |
|
8 |
8 |
Combined vaccine prevents 6 diseases: (Diphtheria - Pertussis - Tetanus - Polio - Hib and Hepatitis B) |
N1/n2/n3/n4/n5 |
After reconstitution, 01 dose (0.5ml) contains: - Diphtheria toxin ≥ 30IU; - Tetanus toxoid ≥ 40IU; - Bordetella pertussis antigens include pertussis toxoid 25mcg and filamentous red blood cell agglutinin 25mcg and Pertactin 8mcg; - Hepatitis B virus surface antigen 10mcg; - Inactivated poliovirus type 1 (Mahoney strain) 40DU; Inactivated poliovirus type 2 (MEF-1 strain) 8DU; Inactivated poliovirus type 3 (Saukett strain) 32DU; - Haemophilus influenza type b polysaccharide 10mcg plus 25mcg tetanus toxoid as carrier protein Or equivalent |
Intramuscularly |
Hib lyophilized powder and suspension for injection suspension |
Bottle/Vial/Tube/Syringe/Dose/Box |
400 |
|
9 |
9 |
Prevention vaccine: measles, mumps, rubella |
N1/n2/n3/n4/n5 |
0.5ml dose contains: Measles virus ≥ 1,000 CCID50; Mumps virus ≥ 12,500 CCID50; Rubella virus ≥ 1,000 CCID50; |
Intramuscularly or subcutaneous |
East dried powder injected |
Bottle/Vial/Tube/Syringe/Dose/Box |
100 |
|
10 |
10 |
Vaccines to prevent: Meningococcal A, C, Y, W Meningococcal Polysaccharide (serogroup A) (unit combination); Meningococcal polysaccharide (serogroup C) (unit conjugation); - Meningococcal polysaccharide (serogroup Y) (unit conjugation); - Meningococcal polysaccharide (serogroup W-135) (unit conjugation); - Diphtheria toxoid protein (Polysaccharide-conjugated protein for all serogroups) |
N1/n2/n3/n4/n5 |
Each dose (0.5 ml) contains: - Meningococcal polysaccharide (serogroup A) (unit conjugation) 4 µg (mcg); - Meningococcal polysaccharide (serogroup C) (unit conjugation) 4 µg (mcg); - Meningococcal polysaccharide (serogroup Y) (unit conjugation) 4 µg (mcg); - Meningococcal polysaccharide (serogroup W-135) (unit conjugation) 4 µg (mcg); - Diphtheria toxoid protein (Polysaccharide-conjugated protein for all serogroups)*(*Diphtheria toxin amount is estimated and depends on the ratio of polysaccharide conjugate to protein) 48 µg (mcg) or equivalent |
Intramuscularly |
Injection |
Bottle/Vial/Tube/Syringe/Dose/Box |
100 |
|
11 |
11 |
Vaccine to prevent: meningococcal meningitis types B, C - Meningococcal periplasmic protein group B - Meningococcal cortical polysaccharide group C |
N1/n2/n3/n4/n5 |
Each 0.5ml dose contains: - Group B meningococcal outer membrane protein 50mcg; - Meningococcal cortical polysaccharide group C 50mcg |
Inject |
Injection |
Bottle/Vial/Tube/Syringe/Dose/Box |
100 |
|
12 |
12 |
Adsorbed tetanus vaccine (TT) |
N1/n2/n3/n4/n5 |
Detoxification refined tetanus ≥ 40 IU/0.5ml |
Inject |
Injection (injection mixture) |
Bottle/Vial/Tube/Syringe/Dose/Box |
5.000 |
|
13 |
13 |
Hepatitis B Vaccine (Pure Hepatitis B Surface Antigen (HBsAg) |
N1/n2/n3/n4/n5 |
≈ 20mcg/1ml |
Intramuscularly |
Suspension for injection/ Suspension is pre-packaged in the injection device |
Bottle/Vial/Tube/Syringe/Dose/Box |
600 |
|
14 |
14 |
Vaccine to prevent Chickenpox Live attenuated chickenpox virus (OKA strain) |
N1/n2/n3/n4/n5 |
≥ 103.3 PFU (0.5ml) |
Subcutaneous |
Dried injection |
Bottle/Vial/Tube/Syringe/Dose/Box |
300 |
|
15 |
15 |
Cervical Cancer Vaccine (L1 HPV protein type 6; L1 HPV protein type 11; L1 HPV protein type 16; L1 HPV protein type 18; L1 HPV protein for each of types 31,33,45,52 and 58) |
N1/n2/n3/n4/n5 |
30mcg L1 HPV type 6 protein; 40mcg L1 HPV type 11 protein; 60mcg L1 HPV type 16 protein; 40mcg L1 HPV type 18 protein; 20mcg HPV L1 protein for each of types 31,33,45,52 and 58 (0.5ml) |
Inject |
Injection/injectable drug in injection tools |
Bottle/Vial/Tube/Syringe/Dose/Box |
200 |
|
16 |
16 |
Cervical Cancer Vaccine (Recombinant quadrivalent vaccine against human HPV types 6, 11, 16, 18 L1 HPV6 protein + L1 HPV11 protein + L1 HPV16 protein + L1 HPV18 protein) |
N1/n2/n3/n4/n5 |
(20mcg L1 HPV6 protein + 40mcg L1 HPV11 protein + 40mcg L1 HPV16 protein + 20mcg L1 HPV18 protein)/Dose (0.5ml) |
Inject |
Injection/injectable drug in injection tools |
Bottle/Vial/Tube/Syringe/Dose/Box |
200 |
|
17 |
17 |
Pneumococcal vaccine (23 strains): 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F |
N1/n2/n3/n4/n5 |
Each dose of vaccine contains (0.5 ml) 25mcg of each of the 23 types |
Intramuscularly |
Injection |
Bottle/Vial/Tube/Syringe/Dose/Box |
200 |
|
18 |
18 |
Vaccine to prevent pneumococcal diseases (23 types) |
N1/n2/n3/n4/n5 |
Each syringe contains a single dose of 0.5ml containing: - Pneumococcal polysaccharide type 1 serum 2.2mcg; - Pneumococcal polysaccharide type 3 serum 2.2mcg; - Pneumococcal polysaccharide type 4 serum 2.2mcg; - Pneumococcal polysaccharide type 5 serum 2.2mcg; - Serum type 6A pneumococcal polysaccharide 2.2mcg; - Serum type 6B pneumococcal polysaccharide 4.4mcg; - Pneumococcal polysaccharide type 7F serum 2.2mcg; - Serum type 9V pneumococcal polysaccharide 2.2mcg; - Pneumococcal polysaccharide type 14 serum 2.2mcg; - Serum type 18C pneumococcal polysaccharide 2.2mcg; - Serum type 19A pneumococcal polysaccharide 2.2mcg; - Serum type 19F pneumococcal polysaccharide 2.2mcg; - Serum type 23F pneumococcal polysaccharide 2.2mcg; - Plus Carrier Protein CRM197 32mcg or equivalent |
Intramuscularly or subcutaneous |
Injection |
Bottle/Vial/Tube/Syringe/Dose/Box |
200 |
|
19 |
19 |
Vaccine to prevent: Meningococcal type B |
N1/n2/n3/n4/n5 |
Each dose (0.5ml) contains: - Recombinant NHBA Neisseria meningitidis group B fusion protein: 50mcg. – Recombinant NadA Neisseria meningitidis group B protein: 50mcg. – Recombinant Neisseria meningitidis group B fHbp fusion protein: 50mcg. – Outer membrane vesicles from Neisseria meningitidis group B strain NZ98/254 were measured as total protein containing PorA P1.4:25mcg. |
Intramuscularly |
Injection |
Bottle/Vial/Tube/Syringe/Dose/Box |
100 |
|
20 |
20 |
Prevention vaccine: Dengue fever |
N1/n2/n3/n4/n5 |
Each 0.5ml dose of vaccine after reconstitution contains: Dengue virus serotype 1 (dengue virus) (live and attenuated) ≥ 3.3 log 10 PFU; Dengue virus serotype 2 (dengue virus) (live, attenuated) ≥ 2.7 log 10 PFU; Dengue virus (dengue virus) serotype 3 (live, attenuated) ≥ 4.0 log 10 PFU; Dengue virus serotype 4 (dengue virus) (live, attenuated) ≥ 4.5 log 10 PFU |
Subcutaneous |
Injected powder |
Bottle/Vial/Tube/Syringe/Dose/Box |
500 |
Downloading files directly on the new Public Procurement System requires a computer using Windows operating system and installing Client Agent software (Linux and MacOS operating systems cannot install Client software yet). Therefore, to be able to download files on smartphones, tablets or computers using operating systems other than Windows, you need to use DauThau.info software to download files.
To download, please Login or Register
- RQ2600027610-01 - Change:Request for quotation code, Project name/purchase estimate (View changes)
- RQ2600027610-00 Posted for the first time (View changes)
Select columns to display
If you are still not our member, please sign up.You can use your account on DauThau.info to log in to Dauthau.Net, and vice versa!
Only 5 minutes and absolutely free! Your account can be use on all over our ecosystem, including DauThau.info and DauThau.Net.
Detailed instructions on how to deposit money and redeem points on DauThau.info
When does contract negotiation fail?
[VIDEO] Guide for bid solicitors to Extend the Bid Submission Deadline
[VIDEO] Guide to Evaluating Bid Documents on the New National Bidding Network System
[VIDEO] Guide to Posting Tender Notices for PPP Projects
[VIDEO] Guide to Posting Prequalification Notices for PPP Projects
[VIDEO] Guide to Responding to Clarification Requests for e-HSMST (E-Prequalification Invitation Documents) of PPP Projects on the New National Bidding Network System
[VIDEO] Guide to Uploading the Shortlist for PPP Projects
Similar goods purchased by Investor Trung tâm Y tế Phú Quốc:
No similar goods purchased by the Investor were found.
Similar goods purchased by other Investor excluding Trung tâm Y tế Phú Quốc:
No similar goods have been found that other Investor have purchased.
Similar goods for which the bidding results of the Ministry of Health have been announced:
No similar goods have been found in the bidding results of the Ministry of Health.